Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Penumbra Inc. (PEN) Insider Trading Activity

    Healthcare • Medical Devices • 4,200 employees

    Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

    Total Value

    -$17,805,945.56

    Total Shares

    -30,667

    Average Trade Value

    -$191,461.78

    Most Active Insider

    Elsesser Adam

    Total Activity: $10,271,980

    Largest Single Transaction

    $1,320,379

    by Elsesser Adam on Dec 20, 2024

    30-Day Activity

    3 Transactions

    Volume: 9,599 shares
    Value: $203,515

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Financial Officer
    Officer
    Mar 5, 2025 900 $142,470 16,143 (+5.6%) Exercise/Conversion
    Chief Accounting Officer
    Officer
    Mar 4, 2025 501 $141,723 32,969 (-1.5%) Sale
    Chief Accounting Officer
    Officer
    Mar 4, 2025 9,200 $202,768 33,470 (+27.5%) Exercise/Conversion
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 32 $9,219 66,779 (-0.0%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 32 $9,190 66,811 (-0.0%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 115 $32,910 66,843 (-0.2%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 32 $9,091 67,075 (-0.0%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 160 $46,326 66,619 (-0.2%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 348 $100,422 25,252 (-1.4%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 2,850 $815,898 25,600 (-11.1%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 886 $250,871 30,672 (-2.9%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 32 $9,055 67,107 (-0.0%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 48 $13,986 66,539 (-0.1%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 26 $7,534 24,270 (-0.1%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 956 $276,169 24,296 (-3.9%) Sale
    Chief Financial Officer
    Officer
    Mar 3, 2025 590 $168,563 16,103 (-3.7%) Sale
    Chief Financial Officer
    Officer
    Mar 3, 2025 300 $85,458 16,693 (-1.8%) Sale
    Director
    Mar 3, 2025 200 $56,444 338,619 (-0.1%) Sale
    Director
    Mar 3, 2025 599 $169,775 338,020 (-0.2%) Sale
    Director
    Mar 3, 2025 816 $232,054 337,204 (-0.2%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 1,672 $476,788 28,450 (-5.9%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 32 $9,293 66,587 (-0.0%) Sale
    Chief Accounting Officer
    Officer
    Mar 3, 2025 550 $156,178 30,122 (-1.8%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 600 $13,224 67,139 (+0.9%) Exercise/Conversion
    Evp, Gen. Counsel Secretary
    Officer
    Mar 3, 2025 117 $33,388 66,958 (-0.2%) Sale
    Director
    Mar 3, 2025 2,000 $580,520 327,619 (-0.6%) Sale
    Chief Financial Officer
    Officer
    Mar 3, 2025 360 $103,946 15,243 (-2.4%) Sale
    Director
    Mar 3, 2025 700 $204,120 326,919 (-0.2%) Sale
    Director
    Mar 3, 2025 2,100 $607,929 329,619 (-0.6%) Sale
    Director
    Mar 3, 2025 300 $86,514 331,719 (-0.1%) Sale
    Director
    Mar 3, 2025 1,678 $480,210 332,619 (-0.5%) Sale
    Chief Financial Officer
    Officer
    Mar 3, 2025 500 $143,215 15,603 (-3.2%) Sale
    Director
    Mar 3, 2025 2,907 $829,774 334,297 (-0.9%) Sale
    Chief Financial Officer
    Officer
    Mar 3, 2025 250 $70,813 16,993 (-1.5%) Sale
    Director
    Mar 3, 2025 50 $14,274 5,573 (-0.9%) Sale
    Director
    Mar 3, 2025 100 $29,213 326,819 (-0.0%) Sale
    Director
    Mar 3, 2025 600 $172,440 332,019 (-0.2%) Sale
    Chief Accounting Officer
    Officer
    Feb 18, 2025 95 $25,758 31,558 (-0.3%) Payment of Exercise Price
    Evp, Gen. Counsel Secretary
    Officer
    Feb 18, 2025 81 $21,962 66,539 (-0.1%) Payment of Exercise Price
    Evp, Gen. Counsel Secretary
    Officer
    Feb 18, 2025 1,840 $0 66,620 (+2.8%) Grant
    Chief Financial Officer
    Officer
    Feb 18, 2025 1,840 $0 17,324 (+10.6%) Grant
    Chief Financial Officer
    Officer
    Feb 18, 2025 81 $21,962 17,243 (-0.5%) Payment of Exercise Price
    Chief Accounting Officer
    Officer
    Feb 18, 2025 1,510 $0 31,653 (+4.8%) Grant
    Chief Accounting Officer
    Officer
    Feb 14, 2025 4,525 $99,731 29,503 (+15.3%) Exercise/Conversion
    Evp, Gen. Counsel Secretary
    Officer
    Feb 14, 2025 780 $0 64,780 (+1.2%) Grant
    Director
    Feb 14, 2025 744 $10,000 3,704 (+20.1%) Grant
    Director
    Feb 14, 2025 744 $10,000 1,409 (+52.8%) Grant
    Director
    Feb 14, 2025 744 $10,000 9,274 (+8.0%) Grant
    Chief Accounting Officer
    Officer
    Feb 14, 2025 640 $0 30,143 (+2.1%) Grant
    Director
    Feb 14, 2025 744 $10,000 6,050 (+12.3%) Grant
    Director
    Feb 14, 2025 744 $10,000 5,623 (+13.2%) Grant
    Director
    Feb 14, 2025 744 $10,000 338,819 (+0.2%) Grant
    Director
    Feb 14, 2025 744 $10,000 1,077 (+69.1%) Grant
    Chief Financial Officer
    Officer
    Feb 14, 2025 780 $0 15,484 (+5.0%) Grant
    Director
    Jan 3, 2025 167 $40,294 8,530 (-2.0%) Sale
    Director
    Jan 2, 2025 170 $40,603 665 (-25.6%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Dec 26, 2024 1,350 $29,754 64,000 (+2.1%) Exercise/Conversion
    CEO and President
    Director, Officer
    Dec 20, 2024 800 $192,632 851,782 (-0.1%) Sale
    CEO and President
    Director, Officer
    Dec 20, 2024 5,435 $1,320,379 842,309 (-0.6%) Sale
    CEO and President
    Director, Officer
    Dec 20, 2024 3,698 $901,979 838,611 (-0.4%) Sale
    CEO and President
    Director, Officer
    Dec 20, 2024 1,029 $251,848 837,582 (-0.1%) Sale
    CEO and President
    Director, Officer
    Dec 20, 2024 4,038 $977,600 847,744 (-0.5%) Sale
    Chief Financial Officer
    Officer
    Dec 15, 2024 599 $147,084 14,704 (-4.1%) Payment of Exercise Price
    Evp, Gen. Counsel Secretary
    Officer
    Dec 15, 2024 794 $194,967 62,650 (-1.3%) Payment of Exercise Price
    Chief Accounting Officer
    Officer
    Dec 15, 2024 300 $73,665 24,978 (-1.2%) Payment of Exercise Price
    Chief Accounting Officer
    Officer
    Dec 3, 2024 5,250 $64,890 25,278 (+20.8%) Exercise/Conversion
    Evp, Gen. Counsel Secretary
    Officer
    Dec 2, 2024 281 $68,887 63,444 (-0.4%) Sale
    Chief Accounting Officer
    Officer
    Dec 2, 2024 654 $158,929 20,028 (-3.3%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Dec 2, 2024 106 $25,783 63,902 (-0.2%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Dec 2, 2024 36 $8,730 64,008 (-0.1%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Dec 2, 2024 177 $43,296 63,725 (-0.3%) Sale
    Chief Accounting Officer
    Officer
    Nov 29, 2024 1,798 $436,123 20,682 (-8.7%) Sale
    CEO and President
    Director, Officer
    Nov 20, 2024 3,281 $782,551 852,582 (-0.4%) Sale
    CEO and President
    Director, Officer
    Nov 20, 2024 2,139 $504,804 865,443 (-0.2%) Sale
    CEO and President
    Director, Officer
    Nov 20, 2024 5,250 $1,242,623 860,193 (-0.6%) Sale
    CEO and President
    Director, Officer
    Nov 20, 2024 4,330 $1,029,198 855,863 (-0.5%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 36 $8,517 64,590 (-0.1%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 376 $90,214 64,169 (-0.6%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 45 $10,751 64,545 (-0.1%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 13 $3,142 64,044 (-0.0%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 112 $26,972 64,057 (-0.2%) Sale
    Evp, Gen. Counsel Secretary
    Officer
    Nov 18, 2024 18 $4,248 64,626 (-0.0%) Sale
    Chief Accounting Officer
    Officer
    Nov 15, 2024 2,570 $0 22,984 (+11.2%) Grant
    Chief Financial Officer
    Officer
    Nov 15, 2024 2,570 $0 15,800 (+16.3%) Grant
    Evp, Gen. Counsel Secretary
    Officer
    Nov 15, 2024 134 $31,871 64,644 (-0.2%) Payment of Exercise Price
    Evp, Gen. Counsel Secretary
    Officer
    Nov 15, 2024 4,290 $0 64,778 (+6.6%) Grant
    Chief Financial Officer
    Officer
    Nov 15, 2024 504 $119,871 15,296 (-3.3%) Payment of Exercise Price
    Chief Accounting Officer
    Officer
    Nov 15, 2024 504 $119,871 22,480 (-2.2%) Payment of Exercise Price
    CEO and President
    Director, Officer
    Oct 21, 2024 3,275 $673,373 868,582 (-0.4%) Sale
    CEO and President
    Director, Officer
    Oct 21, 2024 5,225 $1,069,662 871,857 (-0.6%) Sale
    CEO and President
    Director, Officer
    Oct 21, 2024 1,000 $206,530 867,582 (-0.1%) Sale
    CEO and President
    Director, Officer
    Oct 21, 2024 3,200 $652,224 877,082 (-0.4%) Sale
    CEO and President
    Director, Officer
    Oct 21, 2024 2,300 $466,578 880,282 (-0.3%) Sale